* Please kindly note that our products and services can only be used to support research purposes (Not for clinical use).
The COVID-19 pandemic is driving research on the SARS-CoV-2 virus to find vaccines and treatment methods. Synthetic peptides are playing a big role in developing vaccines. Researchers from the University of Oxford have used in silico methods to identify 63 peptides as potential vaccine targets. In addition to vaccines, peptides are also being investigated as therapeutics to treat or prevent infection with the SARS-CoV-2 virus. Researchers' studies verified that EK1 (a pan-coronavirus fusion inhibiting peptide) could significantly inhibit infection in ACE2 espressing 293T cells. The other research group has reported that linking cholesterol through a PEG4 linker to the C-terminal of EK1 produced a product (EK1C4) with potent inhibitory activity against SARS-CoV-2.
From drug discovery to vaccine development, Creative Peptides has developed a comprehensive range of products and services that scientists can use to accelerate COVID-19/SARS-CoV-2 research and development.
Product Name | Inquiry |
---|---|
(Biotin-LC)-SARS-CoV-2 Spike RBM (receptor binding motif), 438-458 | Inquiry |
96-well Overlapping Peptide Library (Spike glycoprotein from SARS-CoV-2) | Inquiry |
SARS-CoV Peptide Antigen | Inquiry |
SARS-CoV Peptide Antigen Neg control | Inquiry |
SARS-CoV Peptide Antigen Pos control | Inquiry |
SARS-CoV T-cell Peptide Antigens Set | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 319-335 | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 319-335-Lys(Biotin-LC) | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 336-347 | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 336-347- Lys(Biotin-LC) | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 348-357 | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 348-357-Lys(Biotin-LC) | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 352-365 | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 352-365-Lys(Biotin-LC) | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 371-394 | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 371-394-Lys(Biotin-LC) | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 395-430 | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 395-430-Lys(Biotin-LC) | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 513-520 | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 513-520-Lys(Biotin-LC) | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 523-541 | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 523-541-Lys(Biotin-LC) | Inquiry |
SARS-CoV-2 Spike RBM (receptor binding motif), 438-458 | Inquiry |
SARS-CoV-2 Spike RBM (receptor binding motif), 450-473 | Inquiry |
SARS-CoV-2 Spike RBM (receptor binding motif), 450-473-Lys(Biotin-LC) | Inquiry |
SARS-CoV-2 Spike RBM (receptor binding motif), 480-496 | Inquiry |
SARS-CoV-2 Spike RBM (receptor binding motif), 480-496-Lys(Biotin-LC) | Inquiry |
SARS-CoV-2 Spike RBM (receptor binding motif), 500-509 | Inquiry |
SARS-CoV-2 Spike RBM (receptor binding motif), 500-509-Lys(Biotin-LC) | Inquiry |
SARS-CoV-2 T-cell Peptide Antigens set | Inquiry |
SARS-CoV-2 Spike glycoprotein, 647-664 | Inquiry |
SARS-CoV-2 Spike glycoprotein, 747-763 | Inquiry |
SARS-CoV-2 Spike glycoprotein, 691-699 | Inquiry |
SARS-CoV-2 Spike glycoprotein, 424-433 | Inquiry |
SARS-CoV-2 Spike glycoprotein, 996-1004 | Inquiry |
SARS-CoV-2 Spike glycoprotein, 976-984 | Inquiry |
SARS-CoV-2 Spike glycoprotein, 958-966 | Inquiry |
SARS-CoV-2 Spike glycoprotein, 957-973 | Inquiry |
SARS-CoV-2 Spike glycoprotein, 902-917 | Inquiry |
SARS-CoV-2 Spike glycoprotein, 891-906 | Inquiry |
SARS-CoV-2 Spike glycoprotein, 1220-1228 | Inquiry |
SARS-CoV-2 Spike glycoprotein, 1192-1200 | Inquiry |
SARS-CoV-2 Spike glycoprotein, 1185-1193 | Inquiry |
SARS-CoV-2 Spike glycoprotein, 1060-1068 | Inquiry |
SARS-CoV-2 Spike glycoprotein, 1011-1028 | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 319-335-Lys(Biotin-Ahx) | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 336-347-Lys(Biotin-Ahx) | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 348-357-Lys(Biotin-Ahx) | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 352-365-Lys(Biotin-Ahx) | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 371-394-Lys(Biotin-Ahx) | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 395-430-Lys(Biotin-Ahx) | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 513-520-Lys(Biotin-Ahx) | Inquiry |
SARS-CoV-2 Spike RBD (receptor binding domain), 523-541-Lys(Biotin-Ahx) | Inquiry |
SARS-CoV-2 Spike RBM (receptor binding motif), 450-473-Lys(Biotin-Ahx) | Inquiry |
SARS-CoV-2 Spike RBM (receptor binding motif), 480-496-Lys(Biotin-Ahx) | Inquiry |
SARS-CoV-2 Spike RBM (receptor binding motif), 500-509-Lys(Biotin-Ahx) | Inquiry |
SARS-CoV-2 Membrane protein, 89-97 | Inquiry |
SARS-CoV-2 Membrane protein, 61-70 | Inquiry |
SARS-CoV-2 Nucleoprotein, 329-353 | Inquiry |
SARS-CoV-2 Nucleoprotein, 329-346 | Inquiry |
SARS-CoV-2 Nucleoprotein, 215-229 | Inquiry |
SARS-CoV-2 Nucleoprotein, 125-139 | Inquiry |
SARS-CoV-2 Nucleoprotein, 325-339 | Inquiry |
SARS-CoV-2 Nucleoprotein, 320-334 | Inquiry |
SARS-CoV-2 Nucleoprotein, 265-274 | Inquiry |
SARS-CoV-2 Nucleoprotein, 260-274 | Inquiry |
SARS-CoV-2 Nucleoprotein, 226-234 | Inquiry |
SARS-CoV-2 Nucleoprotein, 40-54 | Inquiry |
SARS-CoV-2 Nucleoprotein, 360-375 | Inquiry |
SARS-CoV-2 Nucleoprotein, 352-369 | Inquiry |
SARS-CoV-2 Nucleoprotein, 351-358 | Inquiry |
SARS-CoV-2 Nucleoprotein, 351-359 | Inquiry |
SARS-CoV-2 Nucleoprotein, 322-331 | Inquiry |
SARS-CoV-2 Nucleoprotein, 316-324 | Inquiry |
SARS-CoV-2 Nucleoprotein, 313-330 | Inquiry |
SARS-CoV-2 Nucleoprotein, 305-319 | Inquiry |
SARS-CoV-2 Nucleoprotein, 305-322 | Inquiry |
SARS-CoV-2 Nucleoprotein, 299-315 | Inquiry |
SARS-CoV-2 Nucleoprotein, 292-308 | Inquiry |
SARS-CoV-2 Nucleoprotein, 222-230 | Inquiry |
SARS-CoV-2 Nucleoprotein, 219-227 | Inquiry |
SARS-CoV-2 Nucleoprotein, 159-167 | Inquiry |
SARS-CoV-2 Nucleoprotein, 138-146 | Inquiry |
(Biotin-Ahx)-SARS-CoV-2 Spike RBM (receptor binding motif) | Inquiry |
Creative Peptides has accumulated a huge library of peptide knowledge including frontier peptide articles, application of peptides, useful tools, and more!
Ziconotide (previously called SNX-111), currently marketed under the brand name of Prialt, is the synthetic form ...
Pramlintide is a synthetic analogue of pancreatic amyloid polypeptide. Pancreatic amyloid polypeptide is a polyp ...
Factors of natural aging Natural aging of the skin results in decreased production and increased degradation of extracellula ...
Trimetazidine is a partial fatty acid oxidation inhibitor that inhibits 3-ketoacyl CoA thiolase, one of the enzymes of fatty ...
PMX-53, a chemically synthesized peptide material, is a potent C5a antagonist in human neutrophils and macrophag ...